Loading...

IASO

ATSE:IASO
Snowflake Description

Fair value with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IASO
ATSE
€179M
Market Cap
  1. Home
  2. GR
  3. Healthcare
Company description

IASO S.A. operates hospitals, and a recovery and rehabilitation center in Europe. The last earnings update was 57 days ago. More info.


Add to Portfolio Compare Print
IASO Share Price and Events
7 Day Returns
0%
ATSE:IASO
1.1%
Europe Healthcare
0.1%
GR Market
1 Year Returns
80.8%
ATSE:IASO
-21.2%
Europe Healthcare
4%
GR Market
IASO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
IASO (IASO) 0% 0.5% 7.2% 80.8% 364.5% 155.6%
Europe Healthcare 1.1% -1.9% -2.3% -21.2% -8.1% 43.4%
GR Market 0.1% 13.9% 15.6% 4% 31% -83.6%
1 Year Return vs Industry and Market
  • IASO outperformed the Healthcare industry which returned -21.2% over the past year.
  • IASO outperformed the Market in Greece which returned 4% over the past year.
Price Volatility
IASO
Industry
5yr Volatility vs Market

IASO Value

 Is IASO undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of IASO to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for IASO.

ATSE:IASO Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 19%
Perpetual Growth Rate 10-Year GR Government Bond Rate 4.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ATSE:IASO
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GR Govt Bond Rate 4.9%
Equity Risk Premium S&P Global 15%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.639 (1 + (1- 29%) (58.65%))
0.936
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.94
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 4.93% + (0.936 * 14.99%)
18.97%

Discounted Cash Flow Calculation for ATSE:IASO using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for IASO is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ATSE:IASO DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 18.97%)
2019 16.76 Est @ 32.03% 14.09
2020 20.76 Est @ 23.9% 14.67
2021 24.54 Est @ 18.21% 14.58
2022 28.04 Est @ 14.23% 14.00
2023 31.24 Est @ 11.44% 13.11
2024 34.21 Est @ 9.49% 12.07
2025 36.98 Est @ 8.12% 10.97
2026 39.63 Est @ 7.16% 9.88
2027 42.21 Est @ 6.49% 8.84
2028 44.75 Est @ 6.03% 7.88
Present value of next 10 years cash flows €120.08
ATSE:IASO DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €44.75 × (1 + 4.93%) ÷ (18.97% – 4.93%)
€334.60
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €334.60 ÷ (1 + 18.97%)10
€58.92
ATSE:IASO Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €120.08 + €58.92
€179.00
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €179.00 / 122.16
€1.47
ATSE:IASO Discount to Share Price
Calculation Result
Value per share (EUR) From above. €1.47
Current discount Discount to share price of €1.47
= -1 x (€1.47 - €1.47) / €1.47
-0.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of IASO is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for IASO's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are IASO's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ATSE:IASO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €0.11
ATSE:IASO Share Price ** ATSE (2019-06-18) in EUR €1.47
Europe Healthcare Industry PE Ratio Median Figure of 61 Publicly-Listed Healthcare Companies 20.91x
Greece Market PE Ratio Median Figure of 97 Publicly-Listed Companies 15.65x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of IASO.

ATSE:IASO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ATSE:IASO Share Price ÷ EPS (both in EUR)

= 1.47 ÷ 0.11

13.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IASO is good value based on earnings compared to the Europe Healthcare industry average.
  • IASO is good value based on earnings compared to the Greece market.
Price based on expected Growth
Does IASO's expected growth come at a high price?
Raw Data
ATSE:IASO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 13.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
12.4%per year
Europe Healthcare Industry PEG Ratio Median Figure of 38 Publicly-Listed Healthcare Companies 1.42x
Greece Market PEG Ratio Median Figure of 22 Publicly-Listed Companies 1.34x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for IASO, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on IASO's assets?
Raw Data
ATSE:IASO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €1.16
ATSE:IASO Share Price * ATSE (2019-06-18) in EUR €1.47
Europe Healthcare Industry PB Ratio Median Figure of 74 Publicly-Listed Healthcare Companies 1.81x
Greece Market PB Ratio Median Figure of 138 Publicly-Listed Companies 0.91x
ATSE:IASO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ATSE:IASO Share Price ÷ Book Value per Share (both in EUR)

= 1.47 ÷ 1.16

1.27x

* Primary Listing of IASO.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IASO is good value based on assets compared to the Europe Healthcare industry average.
X
Value checks
We assess IASO's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. IASO has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

IASO Future Performance

 How is IASO expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover IASO, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is IASO expected to grow at an attractive rate?
  • IASO's earnings growth is expected to exceed the low risk savings rate of 4.9%.
Growth vs Market Checks
  • IASO's earnings growth is positive but not above the Greece market average.
  • Unable to compare IASO's revenue growth to the Greece market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ATSE:IASO Future Growth Rates Data Sources
Data Point Source Value (per year)
ATSE:IASO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 12.4%
Europe Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 12.5%
Europe Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 6.6%
Greece Market Earnings Growth Rate Market Cap Weighted Average 16.5%
Greece Market Revenue Growth Rate Market Cap Weighted Average 4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ATSE:IASO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ATSE:IASO Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
ATSE:IASO Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 99 17 13
2018-09-30 104 13 16
2018-06-30 108 9 18
2018-03-31 111 11 15
2017-12-31 114 13 12
2017-09-30 117 11 11
2017-06-30 119 10 9
2017-03-31 118 10 6
2016-12-31 117 9 4
2016-09-30 110 10 6
2016-06-30 107 5 7
2016-03-31 110 10 12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • IASO's earnings are expected to grow by 12.4% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if IASO is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ATSE:IASO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from IASO Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ATSE:IASO Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
ATSE:IASO Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 0.11
2018-09-30 0.13
2018-06-30 0.15
2018-03-31 0.12
2017-12-31 0.10
2017-09-30 0.09
2017-06-30 0.07
2017-03-31 0.05
2016-12-31 0.03
2016-09-30 0.05
2016-06-30 0.06
2016-03-31 0.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if IASO will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess IASO's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
IASO has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

IASO Past Performance

  How has IASO performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare IASO's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • IASO has delivered over 20% year on year earnings growth in the past 5 years.
  • IASO's 1-year earnings growth is less than its 5-year average (4.4% vs 55.6%)
  • IASO's earnings growth has not exceeded the Europe Healthcare industry average in the past year (4.4% vs 6%).
Earnings and Revenue History
IASO's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from IASO Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ATSE:IASO Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 99.25 13.04 7.21
2018-09-30 103.67 15.52 8.34
2018-06-30 108.09 18.00 9.46
2018-03-31 111.12 15.25 9.75
2017-12-31 114.16 12.50 10.03
2017-09-30 116.52 10.50 10.52
2017-06-30 118.89 8.51 11.01
2017-03-31 117.70 6.36 11.17
2016-12-31 116.51 4.20 11.34
2016-09-30 109.50 6.33 14.32
2016-06-30 107.11 7.49 12.56
2016-03-31 109.83 12.00 12.33
2015-12-31 109.27 10.31 11.84
2015-09-30 110.76 0.35 8.90
2015-06-30 113.35 -1.70 10.20
2015-03-31 113.93 -5.39 10.66
2014-12-31 116.53 -3.05 10.96
2014-09-30 108.82 -5.62 12.89
2014-06-30 111.28 -4.58 12.26
2014-03-31 108.44 -0.22 11.95
2013-12-31 107.07 -1.58 11.98
2013-09-30 124.08 10.93 10.74
2013-06-30 121.54 10.50 10.36
2013-03-31 122.39 4.22 10.77
2012-12-31 124.14 3.86 10.42
2012-09-30 121.75 -0.16 9.15
2012-06-30 121.91 -1.81 10.37

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • IASO has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • IASO used its assets more efficiently than the Europe Healthcare industry average last year based on Return on Assets.
  • IASO has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess IASO's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
IASO has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

IASO Health

 How is IASO's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up IASO's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • IASO is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • IASO's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of IASO's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from IASO Company Filings, last reported 5 months ago.

ATSE:IASO Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 141.86 105.17 25.50
2018-09-30 141.86 105.17 25.50
2018-06-30 125.21 105.07 9.60
2018-03-31 125.21 105.07 9.60
2017-12-31 123.48 128.57 16.03
2017-09-30 123.48 128.57 16.03
2017-06-30 108.10 158.17 13.74
2017-03-31 108.10 158.17 13.74
2016-12-31 102.35 162.15 16.23
2016-09-30 102.35 162.15 16.23
2016-06-30 100.73 163.83 12.96
2016-03-31 100.73 163.83 12.96
2015-12-31 99.68 163.91 15.49
2015-09-30 96.65 162.85 9.79
2015-06-30 96.72 162.96 11.42
2015-03-31 92.28 162.91 7.35
2014-12-31 93.84 163.08 7.12
2014-09-30 106.60 163.78 8.69
2014-06-30 107.14 165.90 11.62
2014-03-31 105.40 166.73 13.28
2013-12-31 103.55 167.07 20.00
2013-09-30 115.58 168.12 11.60
2013-06-30 114.54 168.41 13.44
2013-03-31 100.73 148.65 11.73
2012-12-31 103.37 152.26 14.98
2012-09-30 137.29 159.07 9.15
2012-06-30 136.92 155.18 11.81
  • IASO's level of debt (74.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (161.3% vs 74.1% today).
  • Debt is not well covered by operating cash flow (15.8%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 4.3x coverage).
X
Financial health checks
We assess IASO's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. IASO has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

IASO Dividends

 What is IASO's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from IASO dividends.
If you bought €2,000 of IASO shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate IASO's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate IASO's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ATSE:IASO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 46 Stocks 1.7%
Greece Market Average Dividend Yield Market Cap Weighted Average of 50 Stocks 4.1%
Greece Minimum Threshold Dividend Yield 10th Percentile 1.3%
Greece Bottom 25% Dividend Yield 25th Percentile 1.9%
Greece Top 25% Dividend Yield 75th Percentile 4.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ATSE:IASO Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
ATSE:IASO Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2013-11-28 0.000 0.000
2013-08-28 0.000 0.000
2013-05-22 0.000 0.000
2013-04-02 0.000 0.000
2012-03-23 0.024 7.689
2011-03-28 0.025 6.680
2011-03-24 0.025 4.351
2010-11-12 0.043 7.557
2010-06-21 0.048 5.316
2009-10-30 0.086 6.357
2009-07-15 0.086 4.608

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as IASO has not reported any payouts.
  • Unable to verify if IASO's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of IASO's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as IASO has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess IASO's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can IASO afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. IASO has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

IASO Management

 What is the CEO of IASO's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Petropoulos Paraskevas
CEO Bio

Mr. Paraskevas P. Petropoulos serves as Chief Executive Officer of IASO S.A. Mr. Petropoulos served as Managing Director of Iaso SA. He served as 2nd Vice-Chairman of Iaso SA. He also serves as Executive Director at Iaso SA.

CEO Compensation
  • Insufficient data for Petropoulos to compare compensation growth.
  • Insufficient data for Petropoulos to establish whether their remuneration is reasonable compared to companies of similar size in .
Management Team Tenure

Average tenure of the IASO management team in years:

1.4
Average Tenure
  • The average tenure for the IASO management team is less than 2 years, this suggests a new team.
Management Team

Stamatiou Georgios

TITLE
President of Board of Directors

Petropoulos Paraskevas

TITLE
CEO & Executive Director

Doulgerakis Emmanouil

TITLE
CEO & Executive Director

Antsaklis Aristeidis

TITLE
CEO & Executive Director
TENURE
1.4 yrs

Psathas Panagiotis

TITLE
CEO & Executive Director
TENURE
1.4 yrs

Vlachousis Antonios

TITLE
2nd Vice President of Board of Directors

Mameletzis Charalambos

TITLE
1st Vice President of Board of Directors

Stylianos Tsiropoulos

TITLE
Group Finance Director
TENURE
8.2 yrs

Dimitris Mortoglou

TITLE
Operations Director

Athanasopoulou Nikoletta

TITLE
Head of Accounting
Board of Directors Tenure

Average tenure of the IASO board of directors in years:

1.4
Average Tenure
  • The average tenure for the IASO board of directors is less than 3 years, this suggests a new board.
Board of Directors

Stamatiou Georgios

TITLE
President of Board of Directors

Petropoulos Paraskevas

TITLE
CEO & Executive Director

Doulgerakis Emmanouil

TITLE
CEO & Executive Director

Antsaklis Aristeidis

TITLE
CEO & Executive Director

Psathas Panagiotis

TITLE
CEO & Executive Director
TENURE
1.4 yrs

Vlachousis Antonios

TITLE
2nd Vice President of Board of Directors
TENURE
4.3 yrs

Mameletzis Charalambos

TITLE
1st Vice President of Board of Directors

Emmanouil Plevris

TITLE
Non-Executive Director
TENURE
1.4 yrs

Sarris Spyridon

TITLE
Non-Executive Director

Vasilopoulos Ioannis

TITLE
Non-Executive Director
TENURE
1.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess IASO's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. IASO has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

IASO News

Simply Wall St News

IASO's (ATH:IASO) Wonderful 454% Share Price Increase Shows How Capitalism Can Build Wealth

(ATH:IASO) share price is up a whopping 454% in the last three years, a handsome return for long term holders. … By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. … Given the importance of this milestone, it's not overly surprising that the share price has increased strongly.

Simply Wall St -

Does IASO S.A. (ATH:IASO) Have A Volatile Share Price?

(ATH:IASO), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

Should You Worry About IASO S.A.’s (ATH:IASO) ROCE?

Specifically, we're going to calculate its Return On Capital Employed (ROCE), in the hopes of getting some insight into the business. … What is Return On Capital Employed (ROCE)? … ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business.

Simply Wall St -

Is IASO S.A.'s (ATH:IASO) P/E Ratio Really That Good?

This article is written for those who want to get better at using price to earnings ratios (P/E ratios). … IASO has a price to earnings ratio of 9.19, based on the last twelve months. … How Do I Calculate A Price To Earnings Ratio

Simply Wall St -

Are IASO S.A.'s (ATH:IASO) Interest Costs Too High?

(ATH:IASO) with its market cap of €142m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

Is IASO SA's (ATH:IASO) 13% Better Than Average?

This article is for those who would like to learn about Return On Equity (ROE). … That means that for every €1 worth of shareholders' equity, it generated €0.13 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Does IASO SA (ATH:IASO) Have A Good P/E Ratio?

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … IASO has a price to earnings ratio of 4.82, based on the last twelve months. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Simply Wall St -

Is IASO SA's (ATH:IASO) Balance Sheet A Threat To Its Future?

IASO SA (ATH:IASO) is a small-cap stock with a market capitalization of €91.86m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Evaluating financial health as part of your investment thesis is

Simply Wall St -

Was IASO SA's (ATH:IASO) Earnings Growth Better Than The Industry's?

Assessing IASO SA's (ATH:IASO) performance as a company requires looking at more than just a years' earnings data. … Below, I will run you through a simple sense check to build perspective on how IASO is doing by comparing its most recent earnings with its historical trend, in addition to the performance of its healthcare industry peers. … IASO's trailing twelve-month earnings (from 31 December 2017) of €12.50m has

Simply Wall St -

Is It Time To Buy IASO SA. (ATH:IASO)?

The stock is currently trading at €0.92 on the share market, which means it is overvalued by 80% compared to my intrinsic value of €0.51. … Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. … If you believe IASO should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable.

Simply Wall St -

IASO Company Info

Description

IASO S.A. operates hospitals, and a recovery and rehabilitation center in Europe. The company offers obstetrics and gynecology services, including gynecological oncology, endoscopic surgery, and pediatric and juvenile gynecology services, as well as delivery and operating rooms. It also provides diagnostics and therapeutics services comprising neonatal audiology; endocrinology, diabetes, and osteoporosis; and medical imaging, fetal medicine-gynecological ultrasounds, recurrent spontaneous abortions, neonatal cardiology, central laboratories, radiation oncology, breast center, cytology, urodynamics, medical oncology, surgical pathology, neonatal pediatrics, and nuclear medicines, as well as plastic, reconstructive, and cosmetic surgery/laser services. In addition, it offers outpatient department services, such as angiology and phlebology, autoimmune rheumatic diseases and pregnancy, cardiology, check-up, colposcopy unit, dermatology, E.N.T, headache, hematology, nutritional support and dietetics, surgery, and veins laser treatment services, as well as endocrinology, diabetes, and osteoporosis services; and ancillary services. Further, the company operates intensive care, neonatal intensive care, and assisted reproduction units. IASO S.A. was founded in 1996 and is based in Athens, Greece.

Details
Name: IASO S.A.
IASO
Exchange: ATSE
Founded: 1996
€179,326,114
122,156,754
Website: http://www.iaso.gr
Address: IASO S.A.
37-39, Kifissias Avenue,
Maroussi,
Athens,
151 23,
Greece
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ATSE IASO Ordinary Shares The Athens Stock Exchange GR EUR 09. Jun 2000
Number of employees
Current staff
Staff numbers
0
IASO employees.
Industry
Health Care Facilities
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/18 20:45
End of day share price update: 2019/06/18 00:00
Last estimates confirmation: 2018/04/26
Last earnings filing: 2019/04/22
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.